Telix Pharmaceuticals reported Q2 2026 revenue of $247 million, up 7% from the previous quarter and 21% year-over-year, driven by strong growth in its Precision Medicine segment. The company is progressing key clinical trials, including a Phase 3 study for prostate cancer therapy and expanding its imaging portfolio. Telix expects full-year 2026 revenue to exceed $1 billion, supported by a $40 million payment from Regeneron and increased R&D investment to accelerate development programs. These developments position Telix for continued growth in targeted cancer diagnostics and treatments.
Bragar Eagel & Squire, P.C. is investigating Regeneron Therapeutics for potentially misleading investors about the progress of its Phase III Fianlimab-Libtayo study. The complaint claims Regeneron made false or misleading statements and failed to dis...
A class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly making false statements about the Phase III Fianlimab-Libtayo trial. The lawsuit claims Regeneron misled investors by overstating the trial's success, causing the s...
Faruqi & Faruqi, LLP is investigating claims against Regeneron Pharmaceuticals for allegedly misleading investors about the Phase III Fianlimab-Libtayo clinical trial results. The lawsuit claims Regeneron concealed flaws in the trial's statistical as...
Regeneron Therapeutics faces a class action lawsuit alleging it misled investors about the viability of its Phase III trial combining Fianlimab and Libtayo for advanced melanoma. The lawsuit claims Regeneron made overly positive statements while hidi...
Levi & Korsinsky, LLP has filed a class action lawsuit against Regeneron Pharmaceuticals, alleging the company misled investors about its Phase III Fianlimab-Libtayo study results. The complaint claims Regeneron made false positive statements while c...
